Common use of Publicity; Use of Names Clause in Contracts

Publicity; Use of Names. Prior to the Effective Date, the Parties shall agree upon the timing and content of an initial press release relating to the execution of this Agreement and its terms. Except to the extent already disclosed in that initial press release, no disclosure of the existence of this Agreement or its terms may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity, news release or promotional materials relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as permitted by this Agreement or as may be required by applicable laws, regulations, or judicial order. The Party desiring to make any such public announcement shall provide the other Party with a written copy of the proposed announcement sufficiently in advance of the public release to allow such other Party to comment upon such announcement, prior to its release. In addition to the foregoing restrictions on public disclosure, if either Party concludes that a copy of this Agreement must be filed with a securities exchange or regulatory or governmental body to which that Party is subject, wherever situated, such Party shall provide the other Party with a copy of this Agreement showing any sections as to which the filing Party proposes to request confidential treatment, will provide the other Party with an opportunity and a reasonable time period to comment on any such proposal and to suggest additional portions of the Agreement for confidential treatment and will take such Party’s comments into consideration before filing the Agreement. If the filing Party disagrees with the other Party’s additional confidential treatment request, the Parties shall attempt in good faith to discuss the matter before the Agreement is filed.

Publicity; Use of Names. Prior to the Effective Date, the Parties Merck and Vertex shall agree upon the timing and content of an initial press release relating to the execution of this Agreement and its termsthe transactions contemplated herein. Except to the extent already disclosed in that initial press release, no disclosure of the existence of this Agreement Agreement, its subject matter or its terms may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity, news release or promotional materials disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as permitted by this Agreement or as may be required by applicable laws, regulations, or judicial order. The Party desiring to make any such public announcement shall provide the other Party with a written copy of the proposed announcement sufficiently in advance of the sufficient time prior to public release to allow such other Party to comment upon such announcement, prior to its public release. In addition to the foregoing restrictions on public disclosure, if either Party concludes that a copy of this Agreement must be filed with a securities exchange or regulatory or governmental body to which that Party is subject, wherever situatedthe Securities and Exchange Commission, such Party shall provide the other Party with a copy of this Agreement showing any sections as to which the filing Party proposes to request confidential treatment, will provide the other Party with an opportunity and a reasonable time period to comment on any such proposal and to suggest additional portions of the Agreement for confidential treatment and will take such Party’s 's reasonable comments into consideration before filing the Agreement. If the filing Party disagrees with the other Party’s 's additional confidential treatment request, the Parties shall attempt have an opportunity to discuss such matter in good faith to discuss the matter before the Agreement is filed.

Publicity; Use of Names. Prior to the Effective Date, the Parties GSK and Vertex shall agree upon the timing and content of an initial press release relating to the execution of this Agreement and its terms. Except to the extent already disclosed in that initial press release, no disclosure of the existence of this Agreement or its terms may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity, news release or promotional materials relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as permitted by this Agreement or as may be required by applicable laws, regulations, or judicial order. The Party desiring to make any such public announcement shall provide the other Party with a written copy of the proposed announcement sufficiently in advance of the sufficient time prior to public release to allow such other Party to comment upon such announcement, prior to its public release. Information redacted pursuant to a confidential treatment request. An unredacted version of the exhibit has been filed separately with the Commission. In addition to the foregoing restrictions on public disclosure, if either Party concludes that a copy of this Agreement must be filed with a securities exchange or regulatory or governmental body to which that Party is subject, subject wherever situated, such Party shall provide the other Party with a copy of this Agreement showing any sections as to which the filing Party proposes to request confidential treatment, will provide the other Party with an opportunity and a reasonable time period to comment on any such proposal and to suggest additional portions of the Agreement for confidential treatment and will take such Party’s 's reasonable comments into consideration before filing the Agreement. If the filing Party disagrees with the other Party’s 's additional confidential treatment request, the Parties shall attempt in good faith have an opportunity to discuss the matter in good faith before the Agreement is filed.

Publicity; Use of Names. Prior to the Effective Date, the Parties Merck and Vertex shall agree upon the timing and content of an initial press release relating to the execution of this Agreement and its termsthe transactions contemplated herein. Except to the extent already disclosed in that initial press release, no disclosure of the existence of this Agreement Agreement, its subject matter or its terms may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity, news release or promotional materials disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as permitted by this Agreement or as may be required by applicable laws, regulations, or judicial order. The Party desiring to make any such public announcement shall provide the other Party with a written copy of the proposed announcement sufficiently in advance of the sufficient time prior to public release to allow such other Party to comment upon such announcement, prior to its public release. In addition to the foregoing restrictions on public disclosure, if either Party concludes that a copy of this Agreement must be filed with a securities exchange or regulatory or governmental body to which that Party is subject, wherever situatedthe Securities and Exchange Commission, such Party shall provide the other Party with a copy of this Agreement showing any sections as to which the filing Party proposes to request confidential treatment, will provide the other Party with an opportunity and a reasonable time period to comment on any such proposal and to suggest additional portions of the Agreement for confidential treatment and will take such Party’s reasonable comments into consideration before filing the Agreement. If the filing Party disagrees with the other Party’s additional confidential treatment request, the Parties shall attempt have an opportunity to discuss such matter in good faith to discuss the matter before the Agreement is filed.

Publicity; Use of Names. Prior to the Effective Date, the Parties Merck and Vertex shall agree upon the timing and content of an initial press release relating to the execution of this Agreement and its termsthe transactions contemplated herein. Except to the extent already disclosed in that initial press release, no disclosure of the existence of this Agreement Agreement, its subject matter or its terms may be made by either Party, and no Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity, news release or promotional materials disclosure relating to this Agreement or its subject matter, without the prior express written permission of the other Party, except as permitted by this Agreement or as may be required by applicable laws, regulations, or judicial order. The Party desiring to make any such public announcement shall provide the other Party with a written copy of the proposed announcement sufficiently in advance of the sufficient time prior to public release to allow such other Party to comment upon such announcement, prior to its public release. In addition to the foregoing restrictions on public disclosure, if either Party concludes that a copy of this Agreement must be filed with a securities exchange or regulatory or governmental body to which that Party is subject, wherever situatedthe Securities and Exchange Commission, such Party shall provide the other Party with a copy of * Information redacted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. this Agreement showing any sections as to which the filing Party proposes to request confidential treatment, will provide the other Party with an opportunity and a reasonable time period to comment on any such proposal and to suggest additional portions of the Agreement for confidential treatment and will take such Party’s reasonable comments into consideration before filing the Agreement. If the filing Party disagrees with the other Party’s additional confidential treatment request, the Parties shall attempt have an opportunity to discuss such matter in good faith to discuss the matter before the Agreement is filed.